Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
SOUTH SAN FRANCISCO, Calif., March 01, 2016 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the management team are scheduled to present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 10:40 a.m. EST. The conference is being held March 7-9, 2016, at the Marriott Copley Place in Boston.
Presenting are Tassos Gianakakos, chief executive officer, and Dr. Jonathan C. Fox, M.D., Ph.D., chief medical officer.
To access the live webcast of MyoKardia’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the conference.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK- 461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies. MyoKardia’s purpose is to improve the lives of patients and families suffering from cardiovascular disease by creating targeted therapies that can change the course of their condition. For more information, please visit www.myokardia.com.
Media Contact: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected] Investor Contact: Matt Clawson Pure Communications, Inc. 949-370-8500 [email protected]
